Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Compound arsenic acid preparation capable of reducing toxicity of arsenic

An arsenous acid preparation and arsenic toxicity technology, which can be used in medical preparations containing active ingredients, pharmaceutical formulations, inorganic active ingredients, etc., and can solve the problems of high arsenic toxicity and hemoglobin damage.

Active Publication Date: 2012-09-19
王喜军
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] Although the existing arsenous acid has obvious inhibitory effect on cancer cells and promotes the apoptosis of cancer cells, animal toxicity tests have shown that its arsenic toxicity is high, and it still seriously damages the heart, liver, kidney, testis, red blood cells and hemoglobin

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compound arsenic acid preparation capable of reducing toxicity of arsenic
  • Compound arsenic acid preparation capable of reducing toxicity of arsenic

Examples

Experimental program
Comparison scheme
Effect test

specific Embodiment approach 1

[0009] Embodiment 1: The compound arsenous acid preparation for reducing arsenic toxicity in this embodiment consists of arsenic trioxide, cimichine and a solvent, wherein the mass ratio of cimichin to arsenic trioxide is 5-12.5:1.

[0010] The compound arsenous acid preparation for reducing arsenic toxicity in this embodiment can be formed by dissolving arsenic trioxide and cimichin in a solvent. The compound arsenous acid preparation for reducing arsenic toxicity in this embodiment can also be made into other dosage forms such as powder or tablet by existing techniques (such as freeze-drying, spray-drying, etc.).

specific Embodiment approach 2

[0011] Embodiment 2: The difference between this embodiment and Embodiment 1 is that the solvent is a sodium chloride solution with a mass concentration of 0.9%. Others are the same as the first embodiment.

specific Embodiment approach 3

[0012] Embodiment 3: The difference between this embodiment and Embodiment 1 or 2 is that the mass ratio of cimicidin to arsenic trioxide is 10:1. Others are the same as the first or second embodiment.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a compound arsenic acid preparation capable of reducing the toxicity of arsenic and relates to a compound arsenic acid preparation containing arsenic trioxide. The compound arsenic acid preparation can be used for solving the problem that the exiting arsenic acid medicament has great toxicity. The compound arsenic acid preparation capable of reducing the toxicity of the arsenic comprises the arsenic trioxide, cimifugin and solvent. The compound arsenic acid preparation capable of reducing the toxicity of the arsenic can reduce the toxicity of the arsenic trioxide, reduce the damages to normal cells, tissues, organs and organisms and have no influence on the treatment effect of arsenic acid on cancer cells.

Description

technical field [0001] The invention relates to a compound arsenous acid preparation containing arsenic trioxide. Background technique [0002] Arsenous acid has a certain effect on acute promyelocytic leukemia (APL), but its mechanism of action is still unclear. The current study shows that the chromosome t translocation (15:17) is an important cytogenetic feature of acute promyelocytic leukemia, which leads to the fusion of the promyelocytic leukemia gene PML and the retinoic acid receptor a (RARa) gene , express PML-RARa protein, the overexpression of this fusion protein is one of the main mechanisms of APL pathogenesis, overexpression of PML-RARa can inhibit cell differentiation and apoptosis. Experiments found that arsenic trioxide brought the cells back into the normal track of programmed death by regulating the level of PML-RARa in NB4 cells. [0003] Arsenic trioxide (dissolved in water to form arsenous acid) can significantly inhibit the growth of human liver canc...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K33/36A61P35/02A61K31/352
Inventor 王喜军牛一民孙晖
Owner 王喜军
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com